This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): H7N1 Vaccine (SNY), PER.C6-based pandemic influenza vaccine
Description: Two influenza subtypes, H5 and H7, have recently caused highly pathogenic avian influenza (bird flu). While most vaccine development has focused on H5N1 strains, avian H7 containing viruses remain a significant pandemic threat and have caused infections in humans in Europe over the last three years.
The H7N1 vaccine used a strain that was developed from an avian influenza virus by the UK's National Institute for Biological Standards andControl (NIBSC) and the University of Reading, UK. A highly pathogenic H7N1 avian influenza virus which caused outbreaks in Italian poultry in 1999 was modified for this vaccine.
Deal Structure: Sanofi pasteur, the vaccines business of sanofi-aventis, entered on December 31, 2003 into a strategic and exclusive agreement with Crucell N.V. to further develop, manufacture and market cell-based novel influenza vaccine products based on Crucell's proprietary PER.C6 cellline technology. The agreement covers both pandemic and seasonal influenza vaccines.
In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The acquisition was declared unconditional and completed in February 2011.
Partners: Johnson & Johnson
Additional information available to subscribers only: